Specify a stock or a cryptocurrency in the search bar to get a summary
Compass Therapeutics Inc.
CMPXCompass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Address: 80 Guest Street, Boston, MA, United States, 02135
Analytics
WallStreet Target Price
7.57 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CMPX
Dividend Analytics CMPX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CMPX
Stock Valuation CMPX
Financials CMPX
Results | 2019 | Dynamics |